372 related articles for article (PubMed ID: 34404440)
1. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
2. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
3. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
4. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
Derman BA; Fonseca R
Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.
Martinez-Lopez J; Wong SW; Shah N; Bahri N; Zhou K; Sheng Y; Huang CY; Martin T; Wolf J
Blood Adv; 2020 Jul; 4(14):3295-3301. PubMed ID: 32706892
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Cavo M; San-Miguel J; Usmani SZ; Weisel K; Dimopoulos MA; Avet-Loiseau H; Paiva B; Bahlis NJ; Plesner T; Hungria V; Moreau P; Mateos MV; Perrot A; Iida S; Facon T; Kumar S; van de Donk NWCJ; Sonneveld P; Spencer A; Krevvata M; Heuck C; Wang J; Ukropec J; Kobos R; Sun S; Qi M; Munshi N
Blood; 2022 Feb; 139(6):835-844. PubMed ID: 34289038
[TBL] [Abstract][Full Text] [Related]
7. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
9. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
Fan H; Wang W; Zhang Y; Wang J; Cheng T; Qiu L; Wang X; Xia Z; An G
Cancer Biol Med; 2023 Jan; 20(1):77-87. PubMed ID: 36647781
[TBL] [Abstract][Full Text] [Related]
10. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
11. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
12. Clinical significance of the lymphocyte-to-monocyte ratio in multiple myeloma patients with negative minimal residual disease: a single-center retrospective analysis.
Suzuki K; Nishiwaki K; Nagao R; Katori M; Fukushima R; Hattori D; Masuoka H; Yano S
Int J Hematol; 2021 Nov; 114(5):599-607. PubMed ID: 34339005
[TBL] [Abstract][Full Text] [Related]
13. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
14. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Guerrero C; Puig N; Cedena MT; Calasanz MJ; Gutierrez NC; Fernandez M; Oriol A; Ríos-Tamayo R; Hernandez MT; Martínez-Martínez R; Bargay J; de Arriba F; Palomera L; Gonzalez-Rodriguez AP; Gonzalez Perez MS; Orfao A; Mateos MV; Martinez-Lopez J; Rosiñol L; Bladé J; Lahuerta JJ; San-Miguel JF; Paiva B
Blood; 2024 Feb; 143(7):597-603. PubMed ID: 38048552
[TBL] [Abstract][Full Text] [Related]
15. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
17. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R; Cedena MT; Wong S; Shah N; Ríos-Tamayo R; Moraleda JM; López-Jiménez J; García C; Bahri N; Valeri A; Sánchez R; Collado-Yurrita L; Martin T; Wolf J; Lahuerta JJ; Martínez-López J
Blood Adv; 2020 May; 4(10):2163-2171. PubMed ID: 32433744
[TBL] [Abstract][Full Text] [Related]
18. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
19. Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
Wolf J; Fonseca R; Muffly L
Clin Adv Hematol Oncol; 2020 Mar; 18 Suppl 9(3):1-16. PubMed ID: 33843875
[TBL] [Abstract][Full Text] [Related]
20. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
